Scaling Up Malaria Control in Africa: An Economic and Epidemiological Assessment by Awash Teklehaimanot et al.
NBER WORKING PAPER SERIES
SCALING UP MALARIA CONTROL IN AFRICA:










The authors would like to thank Drs. Simon Hay and Robert Snow for providing the Lysenko and
malaria risk maps for our use. In addition, Dr. Yemane Ye-ebiyo Yihdego was enormously helpful
in clearing up details in the costing. Dr. Maru Aregawi Weldedawit kindly provided some references
in the epidemiology literature. Finally, thanks to Adam Storeygard and Yuri Gorokhovich for answering
questions on GIS software. The views expressed herein are those of the author(s) and do not necessarily
reflect the views of the National Bureau of Economic Research.
© 2007 by Awash Teklehaimanot, Gordon C. McCord, and Jeffrey D. Sachs. All rights reserved. Short
sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided
that full credit, including © notice, is given to the source.Scaling Up Malaria Control in Africa: An Economic and Epidemiological Assessment
Awash Teklehaimanot, Gordon C. McCord, and Jeffrey D. Sachs




This paper estimates the number of people at risk of contracting malaria in Africa using GIS methods
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is US$3.0 billion per year on average, or around US$4.02 per African at risk.
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  The burden of malaria in Africa continues to be extremely high, despite the existence of 
effective interventions to curb the mortality and morbidity of the disease. Every year, up to three 
million people die from malaria on the continent.
1 The Millennium Development Goals set in 
2000 recognize that malaria must be controlled if Africa is to escape from the cycle of extreme 
poverty and disease. The MDG on malaria is to “Have halted by 2015 and begun to reverse the 
incidence of malaria,” which has been made more specific by the UN Millennium Project’s 
working group on malaria as “Reduce malaria morbidity and mortality by 75 percent by 2015 
from the 2005 baseline level.” In January 2005, the working group on malaria recommended that 
countries where malaria is rife should use an integrated package of preventive and treatment 
methods to achieve this goal.
2 The project also recommended that insecticide treated mosquito 
bed nets and effective malaria drugs be given away free of charge, a move endorsed by UN 
Secretary-General Kofi Annan in March, and by heads of state at the UN World Summit in 
September 2005. 
There are existing, effective methods to control malaria: prevent people from being bitten 
by mosquitoes — using insecticide treated bed nets and insecticide spray applications — treat 
those who get infected with effective drugs such as artemisinin-based combination therapies 
(ACTs), promote health education and communication, and conduct monitoring and evaluation. 
This paper estimates the number of people at risk of contracting malaria in Africa using GIS 
methods, and then estimates the yearly costs of covering the population at risk with the package 
of interventions recommended by the UN Millennium Project.  
DERIVATION OF POPULATION AT RISK   3
Due to lack of adequate data collection in Africa’s health system, there is incomplete 
information on the morbidity and mortality associated with malaria.
3 The WHO Global Burden 
of Disease program estimates burden in Africa through “active” case-detection studies of 
populations living under different transmission intensity risks, which is subject to under-
detection. Several alternative studies have estimated population at risk using other methods, 
including estimates based on national surveys,
4 estimates based on climate suitability for malaria 
transmission,
5,6 and estimates based on maps of the geographic extent of malaria in a Geographic 
Information System (GIS).
7  
We follow the GIS-based strategy by overlaying the following maps: a high-resolution 
(30 arc-seconds) map of 2005 human population;
8 a map of country boundaries, the most recent 
(2002) map of the extent malaria of risk
9 (shown below); a map of malaria endemicity levels 
constructed in 1968
10 (shown below); and a map of the extent of urban areas.
8 The latter four 
maps were rasterized to the same 30 arc-second cell size. Population sums were then calculated 
by country for the following categories: total population within the malaria risk zone, population 
within a malaria risk zone and within an urban zone, population within a malaria risk zone and 
within a zone of unstable malaria transmission (either hypoendemic or mesoendemic zones in the 
endemicity map), and population within a malaria risk zone, an urban zone, and a zone of 
unstable transmission. (Note that areas showing up on the 1968 endemicity map but are outside 
the area of 2002 malaria risk are considered to no longer have malaria and are ignored). The 
resulting estimate for population at risk of malaria in Africa in 2006 is 672 million people, of 
which 485 million are in rural areas (see Table 1). Finally, we used the UN Population Division’s 
median forecast of projected population to calculate a population growth rate for each country, 
and used it to estimate the population in each country in the above categories for every year   4
between 2006 and 2015. This now allows us to calculate the cost of each intervention, by country 





DESCRIPTION OF COMPREHENSIVE INTERVENTIONS 
The interventions included in this costing exercise encompass most of the key interventions 
recommended by the UN Millennium Project, and many details of the costing follow those of the 
report of the Working Group on Malaria.
2 For prevention of disease, they include long-lasting 
insecticidal bed nets (LLINs), indoor residual spraying (IRS) in unstable transmission areas, 
training of community health workers, and cost of an information, education, and 
communication program. For enhanced diagnosis and treatment, they include microscopy, rapid 
diagnostic tests, effective drugs such as artemisinin-combination therapies (ACTs) for 
uncomplicated malaria, and treatment of severe malaria. Finally, the costing includes resources   5
for monitoring and evaluation, and for the overhead costs of a global push on malaria control. 
Below are the assumptions made for each intervention: 
 
•  Long-Lasting Insecticidal Nets (LLINs): Following the UN Millennium Project’s 
recommendation, we calculate the cost of complete coverage of LLINs for the population 
at risk by the end of 2008, with a ramp-up of coverage during 2006, 2007, and 2008. 
Note that this is a more ambitious target than other costing exercises; the efficacy of 
LLINs and the mass action effect implies that the entire population, and not just children 
and pregnant women, should be targeted by LLIN distribution programs.
11 We assume 
that one net is needed for every two people at risk. The cost of LLINs is around $5, with 
an additional $2 estimated cost of storage and distribution, and the net needs to be 
replaced after 5 years (as is the case with Olyset nets).
12 Note that long-lasting nets do not 
need to be re-impregnated with insecticide during their 5-year lifespan. 
 
•  Indoor Residual Spraying (IRS): Selective vector control (including IRS) was part of 
the WHO’s Global Strategy for Malaria Control which was adopted by the Ministerial 
Conference in 1992 and subsequently endorsed by the World Health Assembly (WHA) 
and the UN General Assembly.  The Global Strategy was also taken up by the RBM 
partnership for the use of selective control in appropriate epidemiological settings.  
Recently, the U.S.’s President’s Malaria Initiative (PMI) has also emphasized the benefits 
of IRS. We have estimated the average annual cost of using IRS against malaria in 
unstable transmission areas at $206 million. However, the cost of blanket spraying all 
malaria transmission areas is $1.1 billion or up to $2 billion considering intense   6
transmission areas require more than one round of spraying per year. Thus blanket 
coverage with IRS seems prohibitively expensive, especially since intense transmission 
areas will be scaling up LLIN coverage, and LLINs are easier to distribute, last for up to 
five years, face less complex logistic challenges than IRS, and require fewer human 
resources. We therefore include costs for IRS in unstable transmission areas only, since 
these areas higher risks of mortality (note that there are some stable transmission areas of 
special economic consideration, such as resorts or mining operations, where private 
sector budgets will cover the high per capita costs of IRS). We assume that Lysenko’s 
map of endemicity in Africa continues to represent relative transmission strength in 
Africa today, since unlike other parts of the world, the continent has benefited from few 
anti-malaria interventions. We consider the areas of the 2002 extent of malaria risk which 
are hypoendemic and mesoendemic in Lysenko’s map to be low- and moderate-
transmission and thus recommended for IRS. (This area, encompassing much of eastern 
African, part of southern Africa and the Sahel countries is roughly the area experts 
describe as having unstable transmission
13). By overlaying this area with the population 
map, we estimate that 149 million people lived in low- and moderate-transmission areas 
in Africa in 2005. We follow the costing methodology of the UN Millennium Project 
Working Group on Malaria. Since costs are at the household level, we assume an average 
of 5 people per household, that each household has about 300 m
2 of surface that needs to 
be sprayed, that each square meter requires 2.67 grams of insecticide (DDT, the 
insecticide of choice), add a ten percent margin of insecticide, and use a cost of US$4.3 
per kilogram of insecticide (this cost corresponds to DDT). In addition, we cost labor 
requirements for IRS. We divide number of households by 360 person-days to get the   7
number of spray persons needed. We assume 5 spray persons for each squad, 5 squads for 
each team and for each technician, and 1 supervisor for 5 teams. Wages were set at 
US$10 per day for the spray persons (for 40 days of work plus 6 training days), US$15 
per day for squad chiefs and technicians (both also for 46 days), and US$20 per day for 
supervisors (for 18 person-days of work). For field equipment, we include a tent 
(US$2000) for each team and each supervisor, and add $100 per person for all personnel 
for coveralls, handgloves, goggles, buckets, soaps, etc., and US$0.06 in forms and 
stationary for each household sprayed. For the first year (2006) we include the cost of the 
spray pump and spare parts (US$500) for each spray person.  Finally, we recognize the 
costs of other logistics, including vehicles to transport equipment and personnel, spare 
parts and maintenance, fuel and lubricant, and insurance for the spraying team and 
vehicles. Since the UN Millennium Project Working Group on Malaria estimated costs 
for these items in Ethiopia based on number of districts, we cannot replicate the costing 
in this exercise (since we are only working with population at risk in each country). We 
therefore totaled these costs (for every year) in the Working Group’s exercise and found 
them to be 30% of the other costs of IRS (which we do model). We therefore added 30% 
of total IRS costs as an estimate of the cost of logistics. 
 
•  Training Community Health Workers (CHW): An RBM survey indicated that 
between 70% and 90% of febrile children are treated at home.
2 There is therefore an 
urgent need to treat uncomplicated malaria at the community level, especially given 
evidence of decreased child mortality among those who see a community health worker 
(CHW).
14 A number of countries are seeking to improve coverage by extending health   8
services using CHWs for malaria diagnosis and treatment services. We assume that one 
CHW is needed per 500 population, and that training for malaria control lasts 8 days and 
costs $10 per day. .  
 
•  Human Resource Development: Note that there are other needs in human resource 
development; the Malaria Working Group indicates that besides CHWs, training of 
nurses, physicians, entomologists and malariologists will be needed to guide and 
implement the program activities. However, these costs are estimated based on the size of 
the formal health sector (number of hospitals, etc.), and are not estimated based on the 
size of the population at risk. We approximate the costs based on the methodology of the 
Working Group on Malaria as follows: we consider the total cost of leadership training 
for program managers and topping up salary for medical officers, epidemiologists, 
entomologists, biologists, health officers, nurses, environmental health workers, and 
malaria technicians. The estimated costs total $704 million for Ethiopia from 2005--2015. 
Using our estimate of population at risk, we find that this number of human resource 
development needs translates into around $1.00 per person at risk per year, and use the 
same assumption for all countries in Africa based on population at risk.  
 
•  Microscopy: We expect that health facilities such as health centers, rural hospitals, and 
all hospitals in urban areas will use microscopic examination of stained thick and thin 
blood smears, the gold standard for malaria diagnosis. The Working Group on Malaria 
estimates the cost of microscopy using the numbers of hospitals and other health centers 
in a country, which cannot be duplicated in this paper. We therefore estimate the cost of   9
microscopy as we did for topping-up of salaries. The Working Group on Malaria 
estimated that the total cost of microscopy for Ethiopia from 2005--2015 to be around 
$29 million. Using our estimates of population at risk, we find that this number is 
equivalent to around $0.04 per person at risk per year, and use this number to estimate 
microscopy costs for all the countries. Note that microscopes can be used for other 
purposes (TB, other parasitic and bacterial diseases). 
 
•  Rapid Diagnostic Testing (RDT): Given that peripheral levels of the health system – 
particularly rural areas – often cannot meet the laboratory requirements for microscopy, a 
variety of simple and rapid diagnostic tests have been developed for accurate and reliable 
malaria diagnosis by community health workers and health facilities. We assume that 
RDT should be used only in unstable transmission areas, for all age groups.  
 
In areas of intense transmission, where severe disease and mortality are largely 
concentrated in children under five years of age, malaria should be treated on the basis of 
clinical suspicion of malaria and not on confirmed diagnosis by RDTs. People older than 
5 years of age have a well developed level of immunity, are at lesser risk of developing 
severe malaria and a significant proportion are asymptomatic in the presence of malaria 
parasites.  This group (above 5 years old living in intense transmission areas) constitutes 
the bulk of the febrile cases in Africa (we estimate around 218 million fever episodes) 
and at the moment will be too expensive to subject every one of them to RDT 
examination. They should therefore be treated clinically on the basis of seasonality and 
clinical manifestation of the disease.    10
 
We use the UN Population Division’s World Population Prospects’ demographic 
breakdown for every year between 2006 and 2015 to divide our population at risk into 
groups aged 0--4, 5--9, 10--14, and 14+. Following WHO guidelines, the first age group 
does not require RDT, since in patients below age 5 every fever episode immediately 
receives malaria treatment due to the possibility of misdiagnosis.
15 Following similar 
assumptions to the costing done by the UN Millennium Project Working Group on 
Malaria, the 5--9 and 10--14 age groups are assumed to experience one fever episode per 
year and the age 14+ group experiences 0.5 fever episodes per year (these are taken as the 
average number of fevers from all causes, across all endemicity levels). One RDT kit is 
needed for each of these fever episodes (again, we restrict ourselves to unstable 
transmission areas), and costs at US$0.61 per kit. Note, that we have built into the model 
a decrease in fever episodes as LLIN coverage increases: we assume that the proportion 
of the population covered by LLINs has a 50% reduction in fever episodes (measured 
reduction in morbidity has ranged from 44%--75%
16,17,18,19). This decreases the need for 
RDT as LLIN coverage increases. Moreover, we have assumed that the number of fever 
episodes for populations living in urban areas is 25% smaller, since transmission tends to 
be lower in urban areas.  
 
•  Artemisinin-based Combination Therapies (ACTs): We again calculated fever 
episodes for each of the four age groups mentioned above (including the 0--4 age group, 
which we assume experience 2 fever episodes per year). We assume that RDT in unstable 
transmission areas will reveal that around 40% of the fevers are due to malaria and   11
require ACTs (as was assumed by the UN Millennium Project Working Group on 
Malaria). In intense transmission areas, on the other hand, we assume that 20% of the 
fever episodes will be examined by microscopy, and these will have a slide positivity rate 
of 40% (Ethiopia’s current slide positivity rate).  The 80% of fevers not examined by 
microscopy all require ACTs. Our total number of fever episodes requiring malaria 
treatment in 2006 is 395 million, which is within the range of other published estimates.
20 
We assume that each treatment course can be treated with either artemether-lumefantrine  
or artesunate-amodiaquine. Artemether-lumefantrine is assumed to cost US$0.45 for the 
0--4 age group, US$0.90 for the 5--9 age group, US$1.35 for the 10--14 age group, and 
US$1.80 for the 14+ age group.
21,22 Artesunate-amodiaquine is estimated to cost US$0.23 
for the children under 1, $0.45 for the 1--6 age group, US$0.80 for the 7--13 age group, 
and $1.48 for the 13+ age group (we use RBM’s recommended dosages
23 and averages of 
prices from Sanofi-Aventis, Ipca, and Cipla,
24 and adjust to match age groups in our 
analysis). We use the average of the cost of artemether-lumefantrine and artesunate-
amodiaquine. As above, we assume a 50% reduction in fever episodes for the population 
covered by LLINs, and 25% fewer fever episodes among urban populations. For intense 
transmission areas, this is a 50% reduction in all fevers; for unstable transmission areas, it 
is a 50% reduction of fevers that needs ACTs, that is, a 50% reduction of the original 
40% of total fevers. ACT production is a bottleneck, as discussed below; we assume that 
enough ACTs will be produced to meet need starting in 2008, but for 2006 and 2007 
there will be a shortage. We include a US$0.10 cost of using other drugs (sulfadoxine-
pyrimethamine (SP)-amodiaquine combination or SP-chloroquine combination) to treat 
the fevers that will not be treated with ACTs in 2006 and 2007. It is expected that in a   12
year’s time, ACTs such as dihydroartemisinin piperaquine will become available, 
resulting in overall increased production and cost reduction. 
 
•  Management of Severe Malaria: We include a rough approximation of management of 
severe malaria, using the median cost of $29.50 for managing a severe malaria case as 
derived by WHO/AFRO.
25 We assume that about 1% of the malaria episodes would 
progress to severe malaria.
26 
 
•  Information, Education and Communication: A program to educate communities and 
promote behavioral change is an important element in successful malaria reduction. The 
program should produce information, education, and communication materials targeting 
health workers, community leaders, and communities; it should use radio spots, 
television, drama and other educational media to increase treatment-seeking behavior, 
compliance, and use of LLINs, target IRS; and organize sensitization and advocacy 
meetings at district, regional, and national levels. The Working Group on Malaria 
estimated that the cost of IEC for Ethiopia $614,000 per year. Using our estimates of 
population at risk, we find that this number is equivalent to around $0.011 per person at 
risk per year, and use this number to estimate IEC costs for all the countries. 
 
•  Monitoring and Evaluation: Monitoring and evaluation are essential components of 
malaria control programs to track effectiveness of the interventions over time. Activities 
involve assessment of routine health services data and periodic community and 
household surveys in order to develop process indicators for implementation, and   13
outcome indicators for case management, prevention, and program impact.
27 In addition, 
the effectiveness of antimalarials and insecticides must be monitored.  Following the 
standard practice in programs funded by the Global Fund to fight AIDS, TB and Malaria, 
we add 7% of costs as monitoring and evaluation. 
 
•  Overhead Costs: Finally, we add 10% of the cost to account for the overhead costs in a 
global effort to reach full coverage of these malaria interventions by 2008. 
 
Using our estimated population at risk and the costing assumptions above, we arrive at the 
projected total yearly costs for all of Africa shown in Table 2 and graphed below: 
 





















































The most striking fact from these numbers is their modest magnitude. Given that we are talking 
about a disease that kills around two million African children every year, the fact that full   14
coverage of LLINs and ACTs (plus the other interventions) costs only $3.00 per African (or 
$4.02 per person at risk of malaria) is astounding and encouraging.  
We examined these numbers in comparison with earlier studies. The UN Millennium 
Project Working Group on Malaria performed a detailed costing of interventions for Ethiopia, 
and arrived at an average of US$238 million per year, which comes to around US$2.70 per 
capita per year (compared to $3.00 in our results above; note that unlike the working group, we 
include salaries for CHWs, without which our per capita cost is $2.29). Another costing estimate 
(Kiszewski A and others, unpublished) of malaria interventions for Africa results in $1.7 billion, 
an equivalent of around US$2.10 per person at risk per year. It is heartening that our GIS-based 
approach and different costing assumptions produce similar results and corroborate the 
magnitude of the per capita cost of these interventions. 
 
SCALING UP TO FULL COVERAGE IN 2008 
Given that our model assumes full coverage of LLINs by the end of 2008, it is instructive 
to look at costs before 2008 carefully. In order to reach full coverage of all interventions by 
2008, the international community needs to begin planning ahead to guarantee sufficient 
production of LLINs and ACT treatment courses. Full coverage in 2008 means that around 352 
million nets must be distributed in Africa by the end of that year. Around 20 million nets have 
been distributed in 2005 (the Global Fund to fight AIDS, TB and Malaria – the largest provider 
of resources for malaria control in Africa – has approved purchases of around 22--31 million 
LLINs between 2005 and 2007, and we looked at the GFATM disbursement reports and found 
that roughly 20 million nets had been distributed in 2005). Our costing model above includes a 
ramping up of distribution to 100 million new nets in 2006, 110 million new nets in 2007, and   15
122 million new nets in 2008. Since production of LLINs by the two producing companies 
(Sumitomo and Vestergaard) in 2006 is currently planned for around 80 million nets, the donor 
countries should commit as soon as possible to funding a scale up of production in 2007 and 
2008 so that full coverage can be reached by 2008. Two other LLIN products from other 
manufacturers are also expected to be in the market soon, which would alleviate the production 
capacity constraint.     
With regard to treatment, the current estimate for production of ACTs in 2006 is 130 
million treatment doses, which is insufficient to meet the estimated 395 million treatments 
needed. In 2006 and 2007, our costing model assumes that fevers that cannot be treated with 
ACTs will be treated with either SP-amodiaquine combination or SP-chloroquine combination, 
which both cost about US$0.10. By 2008, we assume that enough ACTs will be produced to 
meet the need, which our projections show to be around 251 million treatment courses. This 
implies a doubling of ACT production between now and 2008. For our model, we use the 
estimated 130 million treatment courses for 2006 production, and in order to ramp up to 251 
million by 2008, we use 200 million as the number of ACT treatments produced in 2007. Again, 
since ACTs are produced by private companies, this increase in production can only happen if 
donors agree in advance to purchase the required treatment courses. 
Note that this costing exercise was carried out in early 2006; since scale up in 2006 has 
been slower than expected, this implies a faster scale up will be needed in 2007 and 2008, and 
full coverage could perhaps be reached by early 2009.  The important point, however, is that full 
coverage can be reached within approximately three years, and average annual costs between 
now and 2015 are not high. 
   16
CONCLUSION 
We have employed a GIS-based method to estimate the population in Africa at risk of 
contracting malaria, and proceeded to calculate the cost of providing this population a 
comprehensive set of interventions to reduce malaria incidence and mortality. The interventions 
in our model are adjusted for urban areas and for unstable transmission areas. Although these 
estimates are rough and cannot replace country-specific malaria planning and cost estimates, the 
exercise shows that a GIS-based costing strategy comes up with comparable results to methods 
that estimate population at risk using survey methods. In areas where survey methods may 
severely underestimate population at risk, GIS-based estimates provide a useful alternative 
method. Ideally, maps of malaria risk and intensity will be updated frequently in the future to 
provide up-to-date estimates given the impact of interventions. Our results make it evident that 
the costs of comprehensive malaria interventions are very low on a per-capita or per-patient 
basis. Nevertheless, full coverage is beyond the reach of African government budgets. Given that 
the disease kills millions, is readily preventable and curable, and has been shown to hamper 
economic development, the international community should seize the opportunity to reduce 
massively this human disease burden at such a low cost. Other public health efforts, such as 
measles and polio campaigns currently underway, present an opportunity to synergize by also 
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0-4 5-9 10-14 14+ 0-4 5-9 10-14 14+
Algeria 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Angola 15.60 4.87 10.73 1.23 0.97 0.86 3.54 1.68 1.32 1.17 4.83
Benin 7.58 2.92 4.66 1.29 1.09 0.95 4.25 0.00 0.00 0.00 0.00
Botswana 0.70 0.25 0.45 0.00 0.00 0.00 0.02 0.08 0.08 0.09 0.42
Burkina Faso 13.88 1.75 12.13 2.57 2.12 1.84 7.36 0.00 0.00 0.00 0.00
Burundi 6.55 0.45 6.09 1.16 0.92 0.84 3.63 0.00 0.00 0.00 0.00
Cameroon 16.54 7.09 9.45 2.42 2.18 2.06 9.64 0.04 0.03 0.03 0.14
Central African Republic 4.00 1.51 2.49 0.62 0.56 0.51 2.26 0.01 0.01 0.01 0.03
Chad 9.14 1.85 7.30 1.25 0.99 0.84 3.42 0.51 0.40 0.34 1.40
Comoros 0.62 0.15 0.47 0.10 0.09 0.07 0.36 0.00 0.00 0.00 0.00
Congo 3.70 2.36 1.33 0.69 0.57 0.48 1.95 0.00 0.00 0.00 0.00
Congo, Dem. Rep. 60.13 17.66 42.48 11.76 9.11 7.60 31.66 0.00 0.00 0.00 0.00
Côte d'Ivoire 17.17 6.91 10.26 2.01 1.81 1.70 7.77 0.59 0.53 0.50 2.27
Djibouti 0.59 0.40 0.19 0.00 0.00 0.00 0.00 0.09 0.08 0.07 0.35
Egypt 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equatorial Guinea 0.50 0.19 0.31 0.09 0.07 0.06 0.28 0.00 0.00 0.00 0.00
Eritrea 4.70 0.60 4.10 0.06 0.05 0.05 0.20 0.74 0.64 0.55 2.40
Ethiopia 57.86 7.57 50.29 3.98 3.45 3.09 13.26 5.70 4.94 4.43 19.01
Gabon 1.32 0.94 0.37 0.18 0.17 0.17 0.80 0.00 0.00 0.00 0.00
Gambia, The 1.44 0.76 0.69 0.22 0.19 0.17 0.87 0.00 0.00 0.00 0.00
Ghana 21.80 7.64 14.16 3.02 2.76 2.63 13.39 0.00 0.00 0.00 0.00
Guinea 9.18 2.83 6.36 1.54 1.30 1.16 5.18 0.00 0.00 0.00 0.00
Guinea-Bissau 1.37 0.40 0.97 0.27 0.21 0.17 0.72 0.00 0.00 0.00 0.00
Kenya 33.03 6.78 26.25 4.31 3.52 3.08 14.60 1.27 1.04 0.91 4.30
Liberia 3.15 1.15 1.99 0.61 0.48 0.40 1.66 0.00 0.00 0.00 0.00
Libya 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Madagascar 18.70 3.57 15.13 2.38 2.13 1.82 8.12 0.70 0.63 0.54 2.39
Malawi 12.72 2.15 10.57 0.53 0.47 0.40 1.56 1.75 1.56 1.31 5.14
Mali 13.40 3.15 10.25 2.38 1.96 1.65 6.45 0.18 0.15 0.13 0.50
Mauritania 1.30 0.34 0.96 0.00 0.00 0.00 0.01 0.22 0.18 0.15 0.73
Morocco 2.53 0.91 1.62 0.05 0.04 0.04 0.31 0.22 0.21 0.21 1.45
Mozambique 20.25 5.82 14.43 3.20 2.80 2.51 10.90 0.14 0.12 0.11 0.47
Namibia 1.10 0.24 0.87 0.09 0.09 0.09 0.39 0.06 0.06 0.06 0.26
Niger 13.01 2.17 10.85 1.27 1.00 0.80 3.18 1.37 1.08 0.86 3.45
Nigeria 128.29 44.66 83.63 21.51 18.42 16.48 71.76 0.02 0.02 0.02 0.07
Rwanda 8.77 0.59 8.17 1.46 1.22 1.10 4.99 0.00 0.00 0.00 0.00
Sao Tome and Principe 0.15 0.06 0.09 0.02 0.02 0.02 0.09 0.00 0.00 0.00 0.00
Senegal 10.64 4.59 6.06 0.82 0.72 0.66 3.01 0.85 0.75 0.69 3.14
Sierra Leone 5.41 1.69 3.71 0.94 0.74 0.64 3.09 0.00 0.00 0.00 0.00
Somalia 10.38 2.36 8.02 0.86 0.71 0.56 2.68 1.00 0.82 0.65 3.11
South Africa 6.15 1.49 4.67 0.02 0.02 0.02 0.13 0.65 0.64 0.64 4.03
Sudan 33.48 10.21 23.27 0.68 0.62 0.56 2.91 4.08 3.73 3.38 17.53
Swaziland 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Tanzania, United Republic o 37.17 11.68 25.49 5.33 4.79 4.35 19.77 0.46 0.41 0.37 1.69
Togo 5.28 1.69 3.60 0.86 0.75 0.67 3.00 0.00 0.00 0.00 0.00
Uganda 27.83 3.51 24.32 5.65 4.44 3.63 13.45 0.14 0.11 0.09 0.33
Zambia 11.59 4.12 7.47 1.09 0.95 0.86 3.45 0.90 0.78 0.71 2.85
Zimbabwe 13.05 4.84 8.21 0.61 0.59 0.60 2.77 1.13 1.09 1.12 5.13
All Africa 671.78 186.85 484.94 89.13 75.11 66.17 288.82 24.58 21.44 19.12 87.42
Total Urban Rural
Table 1: Population at Risk in 2006 (millions)
By Endemicity Level
Intensive (Holoendemic + Hyperendemic) Unstable (Mesoendemic + Hypoendemic)
By Age Group By Age Group
 
Table 2: Cost Estimates:
Totals (millions of US$) 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Average
LLINs 700 770 854 58 199 760 831 916 121 263 547
IRS 223 187 191 195 200 204 209 213 218 222 206
CHW 645 660 676 692 708 724 741 758 776 793 717
Microscopy 28 28 29 30 30 31 32 33 33 34 31
Human Resources 677 693 709 726 743 760 778 796 814 832 753
R D T 4 03 32 52 62 62 72 72 82 92 92 9
ACTs 109 168 212 217 222 227 232 238 243 249 212
O t h e r  d r u g s 2 6 1 3000000004
S e v e r e  M a l a r i a 5 44 53 43 53 63 63 73 83 94 03 9
I E C 77788888998
Monitoring & Evaluation 176 182 192 139 152 194 203 212 160 173 178
Global Overhead Costs 268 279 293 212 232 297 310 324 244 264 272
Total 2,953 3,065 3,222 2,337 2,556 3,270 3,408 3,564 2,684 2,908 2,997
Total per total population (dollars) $3.24 $3.29 $3.39 $2.41 $2.58 $3.23 $3.30 $3.38 $2.49 $2.65 $3.00
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